Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

OBJECTIVE: Chronic obstructive pulmonary disease (COPD) represents a burden on patients and health systems. Roflumilast, an oral, selective phosphodiesterase-4-inhibitor reduces exacerbations and improves lung function in severe/very severe COPD patients with a history of exacerbations. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Samyshkin, Yevgeniy, Schlunegger, Michael, Haefliger, Susan, Ledderhose, Sabine, Radford, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563314/
https://www.ncbi.nlm.nih.gov/pubmed/23386787
http://dx.doi.org/10.2147/COPD.S37486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563314/
https://www.ncbi.nlm.nih.gov/pubmed/23386787
http://dx.doi.org/10.2147/COPD.S37486

Ejemplares similares